Moderna announced that the first participant was dosed in a Phase I trial of the company’s HIV trimer mRNA vaccine, mRNA-1574.
Moderna plots vaccines against 15 pathogens with future pandemic potential
Business, Chikungunya virus, Coronavirus Disease (COVID-19) Pandemic, Crimean-Congo hemorrhagic fever (CCHF), Dengue Fever, Ebola, HIV Vaccines, Kenya, Low-Income Countries, Malaria, Marburg Virus, MERS, Middle-Income Countries, Moderna, Mosquito-Borne Infections, National Institutes of Health, Pandemics, Patents, Pathogens, R&D, Vaccines, Viral InfectionsModerna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
Don’t Count Out Omicron Sibling BA.2, and More COVID-19 News
BNT162b2 (Pfizer and BioNTech), Brain, Business, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Vaccines, Covid Brain Fog, COVID-19 cases, COVID-19 Vaccines, Cytokines, Data, Delta Variant (B.1.617.2; India), Denmark, FDA, HIV, HIV Vaccines, Long COVID, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), Omicron BA.2, R&D, Researchers, Stanford University, The Bill and Melinda Gates Foundation, University of California, San FranciscoThe prevailing theory about the Omicron variant is that it is going to rip through the population quickly and possibly burn out, marking the downside of the COVID-19 pandemic. But researchers are expressing concern about a subvariant of Omicron dubbed BA.2 that appears to be tearing through Denmark, just as the first Omicron wave subsided.
Johnson & Johnson announced that the company’s Imbokodo Phase IIb trial in HIV failed to hit the primary endpoint. The study evaluated J&J’s investigational HIV vaccine regimen in young women in sub-Saharan Africa at high risk of acquiring HIV.
University of Oxford researchers started clinical trials for a new vaccine that can potentially target a wide range of human immunodeficiency virus (HIV) variants.
Covid-19 Vaccine Shelved After False HIV Positives Affirms Need for Multiple Vaccines
Australia, Clinical Trials, COVID-19 cases, COVID-19 Vaccines, False-Positive Covid-19 Test Results, HIV Vaccines, Japan, Novel Coronavirus, R&D, Researchers, Russia, South Africa, The Wall Street Journal, Tissue, United StatesA Covid-19 vaccine being developed by CSL Ltd. and the University of Queensland was scrapped after numerous vaccine recipients reported receiving false positives on certain HIV tests, according to the Wall Street Journal.
NIAID Creates Clinical Trials Network
"Operation Warp Speed" Initiative, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Vaccines, HIV Vaccines, Infectious Diseases, Monoclonal Antibodies, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, R&DThe National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
The National Institutes of Health (NIH) ceased administration of an investigational HIV vaccine after interim data revealed that the treatment was not working in preventing the virus.
Johnson & Johnson plans to conduct a late-stage study of the company’s investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.